A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

Phase 3CompletedNCT00209950

H. Lundbeck A/S200 enrolled

Overview

To evaluate the safety and tolerability of gaboxadol in primary insomnia

To evaluate long-term safety of gaboxadol in healthy adults.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with a diagnosis of primary insomnia

Non-US study, principal location:

Regensburg, Germany

Safety

Tolerability

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.